Regularized binormal ROC method in disease classification using microarray data by unknown
BioMed CentralBMC Bioinformatics
ssOpen AcceMethodology article
Regularized binormal ROC method in disease classification using 
microarray data
Shuangge Ma*1, Xiao Song1 and Jian Huang2
Address: 1Department of Biostatistics, University of Washington, Seattle, WA 98195, USA and 2Department of Statistics & Actuarial Science and 
Program in Public Health Genetics, University of Iowa, Iowa City, IA 52242, USA
Email: Shuangge Ma* - shuangge@u.washington.edu; Xiao Song - songx@u.washington.edu; Jian Huang - jian@stat.uiowa.edu
* Corresponding author    
Abstract
Background: An important application of microarrays is to discover genomic biomarkers, among
tens of thousands of genes assayed, for disease diagnosis and prognosis. Thus it is of interest to
develop efficient statistical methods that can simultaneously identify important biomarkers from
such high-throughput genomic data and construct appropriate classification rules. It is also of
interest to develop methods for evaluation of classification performance and ranking of identified
biomarkers.
Results: The ROC (receiver operating characteristic) technique has been widely used in disease
classification with low dimensional biomarkers. Compared with the empirical ROC approach, the
binormal ROC is computationally more affordable and robust in small sample size cases. We
propose using the binormal AUC (area under the ROC curve) as the objective function for two-
sample classification, and the scaled threshold gradient directed regularization method for
regularized estimation and biomarker selection. Tuning parameter selection is based on V-fold
cross validation. We develop Monte Carlo based methods for evaluating the stability of individual
biomarkers and overall prediction performance. Extensive simulation studies show that the
proposed approach can generate parsimonious models with excellent classification and prediction
performance, under most simulated scenarios including model mis-specification. Application of the
method to two cancer studies shows that the identified genes are reasonably stable with
satisfactory prediction performance and biologically sound implications. The overall classification
performance is satisfactory, with small classification errors and large AUCs.
Conclusion: In comparison to existing methods, the proposed approach is computationally more
affordable without losing the optimality possessed by the standard ROC method.
Background
Microarray experiments that monitor gene expression
profiles associated with different disease phenotypes have
become commonplace in biomedical research. Each DNA
sequence represented in microarrays can be considered a
potential biomarker. Classification and prediction using
such genomic measurements may contribute to a better
understanding of the genetic pathways involved in dis-
eases, and hence may lead to better diagnosis of disease
and better prescription of treatment. Analysis of genomic
data is challenging due to high dimensionality of data and
low sample size. Although the number of genes assayed is
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are associated with variations of phenotypes. By employ-
ing standard methods directly, we usually obtain esti-
mates that are not "regular", i.e., estimates are not unique
or ill-behaved. Regularization, through which we achieve
unique and well-behaved estimates, is usually needed.
Regularization can be achieved via model reduction or
variable selection methods.
Several dimension reduction techniques have been
employed for classification using genomic data. Examples
include the partial least squares [1], the principal compo-
nent regression [2], and the singular value decomposition
under the Bayesian framework [3,4], among others. By
using low dimensional projections of covariates as fea-
tures in model estimation, one may obtain estimators
with better prediction performance due to the bias-vari-
ance tradeoff. One drawback of such dimension reduction
techniques is that all genes are used in estimation and pre-
diction. Biological interpretation of such classifiers are
usually not straightforward. Moreover, if certain genes are
not associated with the clinical outcome, it is important to
exclude them from the predictive model.
An alternative approach to the dimension reduction tech-
niques is to use methods that are capable of simultaneous
biomarker selection and model fitting, which can be real-
ized by penalization. Such methods include the least
absolute shrinkage and selection operator-LASSO [5], the
least angle regression-LARS [6], and the threshold gradi-
ent directed regularization method-TGDR [7]. These
methods can produce parsimonious models with a small
number of biomarkers and hence more lucent biological
interpretations.
In this article, we propose an approach for simultaneous
estimation and biomarker selection using a scaled TGDR
method.
It is important to assess both false-positive and false-neg-
ative errors, since the clinical and financial consequences
of the two types of errors can differ significantly. A com-
mon practice is to use the receiver operating characteristic
(ROC) curve [8,9], where the classification performance
can be measured by the area under the ROC curve (AUC).
Advantages of the ROC method include: (1) it does not
assume a parametric form of the class probability. This is
different from the logistic regression method. Although
one can construct an ROC curve from logistic regression,
it assumes a parametric form of the class probability. This
parametric assumption may be not be satisfied; (2) it is
adaptable to outcome-dependent samplings, for example
the case control design; and (3) it is capable of penalizing
false positives and false negatives differently. Therefore,
the ROC method may be preferable in biomarker selec-
tion and classification using genomic measurements.
Pepe [10] proposed the empirical AUC as the objective
function for combining multiple biomarkers in a low
dimensional setting. Ma and Huang [11] proposed a
smooth sigmoid approximation of the empirical AUC for
high-dimensional data. An alternative to the empirical
AUC is the binormal AUC [8]. The binormal AUC tech-
nique was developed parallel to, but separated from the
empirical AUC method. For small sample sizes, the
empirical AUC may change dramatically due to small per-
turbations and differ significantly from the expected AUC,
whereas the binormal AUC is more stable. Studies with
low-dimensional biomarkers show that the binormal
AUC may provide valuable information beyond the
empirical AUC [8]. For data with high dimensional cov-
ariates or large sample sizes, the binormal AUC is compu-
tationally much more affordable than the empirical AUC.
Since both the empirical AUC and the binormal AUC are
extensively used in low dimensional settings, it is of great
interest to extend the study of [11] and explore use of the
binormal AUC for disease classification with microarray
data.
In this article, we proposed an approach for biomarker
selection and classification with microarray data by opti-
mizing the binormal AUC. The scaled TGDR method,
which is a modified version of the TGDR, is adopted for
estimation and biomarker selection. Tuning parameters
are selected using V-fold cross validation, and Monte
Carlo based methods are proposed for evaluation pur-
poses. We assess the proposed approach by extensive sim-
ulation studies and demonstrate it on two cancer datasets.
Comparing to the method in [11], which uses a smoothed
version of the empirical AUC as the objective function, the
contributions of this paper are as follows. First, the binor-
mal AUC, which is at least as important as the empirical
AUC, is used as the objective function. Second, we pro-
pose using the scaled TGDR, which can significantly
reduce the computational cost. Moreover, the occurrence
index, which is a way to rank the selected biomarkers and
measure their relative stability in the presence of sampling
variation, is proposed in this paper.
Results
Simulation studies
Simulation studies are used to examine the finite sample
performance of the proposed regularized ROC method. In
simulation study I, we look at the case where the genes are
assumed to be independently normally distributed. This
setting satisfies all the assumptions for the binormal ROC
method [8] and the underlying model is the logistic
regression model. In simulation study II, we consider
independent genes with marginal distributions other thanPage 2 of 16
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since the linear predictors for both the diseased and non-
diseased groups are normally distributed after a common
monotone transformation. We investigate the perform-
ance of the proposed method when the transformation is
intentionally neglected and the marginal normality
assumption is violated. In simulation study III, we study
the effect of correlations among genes. In simulation
study IV, we investigate the case where marginal normal-
ity cannot be obtained with simple transformations. The
simulation settings are related to but much more compre-
hensive than those in [11].
Using simulation settings similar to those in [12], we first
generate d = 1000 dimensional vectors from the diseased
and non-diseased populations. We consider the following
sample size combinations (nD, nH) = (15, 15), (10, 20),
(50, 50) and (30, 70), where nD and nH denote the
number of samples in the groups with Y = 1(diseased) and
Y = 0 (non-diseased), respectively. Different marginal and
joint distributions of the genes are considered, represent-
ing a variety of data structures encountered in real medical
studies. We assume a model in which a fraction π of the
potential biomarkers are differentially expressed and
hence associated with the binary outcome of interest.
Simulation study I
All the 1000 biomarkers are assumed to be independent
and normally distributed with variance 1. We consider π
= 0.01, π = 0.05 and π = 0.25, which represent the cases
where a small number, a moderate number and a large
number of biomarkers are associated with the outcome.
Moreover, we investigate the following three scenarios:
1. (Small effect) There is a shift of 0.5 in the mean expres-
sion levels for the differentially expressed biomarkers;
2. (Moderate effect) The fold change is 1.5 unit difference
in mean;
3. (Large effect) A shift of 5 units in the mean is consid-
ered.
The underlying model is the logistic regression model
with regression coefficients equal to two times the mean
shifts for genes differentially expressed and zero for the
rest.
For each simulated dataset, we first randomly sample a
training set of size 2/3 × (nD + nH) without consideration
of the stratification of the binary outcome. The testing set
is composed of the rest observations. We construct the
proposed ROC estimate based on the training set only.
Tuning parameters are selected using 3-fold cross valida-
tion. The predictive classification error and binormal AUC
are computed for the testing set based on the estimate
obtained from the training set. Summary statistics based
on 200 simulated datasets are given in Table 1.
It can be seen that for moderate and large effect cases, the
binormal AUCs are close to 1 with very small classifica-
tion errors. The classification performance for small mean
shift cases is less satisfactory, although still acceptable
when the sample size is not too small, due to the relatively
small signal to noise ratios. As sample size increases, the
classification performance improves. The classification
performance also improves with more differentially
expressed genes. The empirical AUCs are very close to the
binormal AUCs. Results for the empirical AUCs are omit-
ted here.
Simulation study II
We consider data settings similar to those in Simulation I,
with π = 0.05 and 1.5 unit shift in mean for differentially
expressed genes. We assume all biomarkers are independ-
ent and marginally distributed as Uniform[- , ]
Gamma(l/4,1/2), and 2 Beta(0.5, 0.5) for the non-dis-
eased group. The diseased group has the same marginal
distributions with only mean shifts. All three marginal
distributions have variance 1 and represent three different
3 3
2
Table 1: Simulation study I. Means of AUC and classification error (with their standard errors in parentheses) for small, moderate and 
large mean differences.
π = 0.01 π = 0.05 π = 0.25
(nH, nD) small moderate large small moderate large small moderate large
(15, 15) AUC 0.63(0.18) 0.88(0.10) 0.99(0.01) 0.64(0.17) 0.92(0.09) 1.00(0.00) 0.71(0.17) 0.95(0.07) 1.00(0.00)
Error 0.37(0.16) 0.16(0.16) 0.00(0.00) 0.37(0.17) 0.12(0.13) 0.00(0.00) 0.32(0.15) 0.07(0.10) 0.00(0.00)
(20, 10) AUC 0.58(0.18) 0.86(0.12) 0.99(0.01) 0.65(0.18) 0.92(0.08) 1.00(0.00) 0.66(0.18) 0.95(0.06) 1.00(0.00)
Error 0.37(0.17) 0.17(0.14) 0.00(0.00) 0.34(0.15) 0.11(0.13) 0.00(0.00) 0.32(0.17) 0.07(0.10) 0.00(0.00)
(50, 50) AUC 0.66(0.09) 0.96(0.03) 1.00(0.00) 0.72(0.09) 0.99(0.01) 1.00(0.00) 0.77(0.09) 0.99(0.01) 1.00(0.00)
Error 0.36(0.09) 0.09(0.06) 0.00(0.00) 0.33(0.08) 0.04(0.04) 0.00(0.00) 0.29(0.08) 0.04(0.04) 0.00(0.00)
(70, 30) AUC 0.66(0.12) 0.95(0.03) 1.00(0.00) 0.70(0.10) 0.98(0.02) 1.00(0.00) 0.77(0.09) 0.99(0.01) 1.00(0.00)
Error 0.32(0.09) 0.09(0.05) 0.00(0.00) 0.29(0.08) 0.05(0.04) 0.00(0.00) 0.24(0.08) 0.03(0.04) 0.00(0.00)Page 3 of 16
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sions; gene expressions with a skewed unimodal distribu-
tion (Gamma); and gene expressions clustering around
the upper and lower limits (Beta). Proper transformations
can lead to marginal normal distributions. We intention-
ally neglect the transformations and employ the proposed
approach directly. The purpose is to investigate the per-
formance of the proposed approach when marginal distri-
bution assumption is violated.
Summary statistics based on 200 simulated datasets are
shown in Table 2. For comparison, we also reproduce the
results from the normal distribution case in Simulation I.
It can be seen that the proposed approach has satisfactory
classification performance under all scenarios. The effect
of different marginal distributions is not significant. The
empirical AUCs are also reasonably close to the binormal
AUCs. Simulation studies with different mean shifts and
different choices of π lead to conclusions similar to those
for simulation study I. Those results are omitted here.
Simulation study III
In simulation studies I and II, possible correlations
among genes have been neglected. In simulation study III,
we investigate the case where the genes are correlated. We
still assume π = 0.05 and 1.5 unit shift in mean for differ-
entially expressed genes. For the non-diseased subjects, let
Zi1, Zi2, ..., i = 1, ..., nH, be a sequence of i.i.d. standard nor-
mal random variables. Denote the d × nH dimensional
gene expression matrix for healthy subjects as X. For the jth
gene of the ith subject, we consider the following models:
1. Model 1:  with k = 10,
m = 7; H = (2Φ - 1), where Φ is the cumulative distri-
bution for the standard normal.
2. Model 2: Same as Model 1, but with k = 10, m = 3.
3. Model 3: Same as Model 1, with H as the identify func-
tion.
4. Model 4: Same as Model 2, with H as the identify func-
tion.
This simulation setting has been considered in [13]. For
models 1 and 2, the genes are marginally uniformly dis-
tributed. For models 3 and 4, the genes are marginally
normally distributed. For genes in models 1 and 3, the
correlations between all genes (differentially and non-dif-
ferentially expressed) are weak; whereas models 2 and 4
are examples of strongly correlated genes. Note that we
not only assume differential genes are correlated, we also
assume differentially expressed and non-differentially
expressed genes are correlated.
Summary statistics based on 200 replicates are shown in
Table 3. For comparison, we also reproduce the results
with independently, marginally uniformly (normally)
distributed genes. We can see from Table 3 that the effects
of correlation are negligible. We looked at other correla-
tion structures and obtained similar results. Moreover the
effect of different marginal distributions are not signifi-
cant.
Simulation study IV
The binormal AUC is theoretically constructed based on
the joint normal distribution assumption on the linear
combination of the covariates in the diseased and non-
diseased population after a common monotone transfor-
mation. We now consider the case when marginal nor-
mality cannot be achieved with simple transformation.
Specifically, we investigate the case when the marginal
gene distributions for the diseased class and the non-dis-
eased class are different. We assume the number of genes
is 1000 and there are 50 subjects in each group. We
assume that π = 0.05 percent genes are differentially
expressed. Moreover, we assume the genes in the non-dis-
eased group are independent and have standard normal
X H Z kij ill j m
j m k= ⎛
⎝⎜
⎞
⎠⎟= −( )× +
−( )× +∑ /1 1
1
3
Table 2: Simulation study II. Means of AUC and classification error (with their standard errors in parentheses) for π = 0.05 and 
moderate mean differences. Marginal distributions: Normal(0, 1), Uniform[- , ] Gamma(1/4, 1/2) and 2 Beta(0.5, 0.5).
(nH, nD) Normal Uniform Gamma Beta
(15, 15) AUC 0.92(0.09) 0.92(0.08) 0.89(0.12) 0.92(0.08)
Error 0.12(0.13) 0.12(0.13) 0.10(0.12) 0.13(0.14)
(20, 10) AUC 0.92(0.08) 0.92(0.08) 0.89(0.12) 0.92(0.08)
Error 0.11(0.13) 0.13(0.12) 0.13(0.13) 0.13(0.13)
(50, 50) AUC 0.99(0.01) 0.99(0.01) 0.95(0.06) 0.99(0.01)
Error 0.04(0.04) 0.04(0.04) 0.06(0.06) 0.03(0.04)
(70, 30) AUC 0.98(0.02) 0.98(0.01) 0.96(0.06) 0.99(0.01)
Error 0.05(0.04) 0.04(0.04) 0.07(0.06) 0.03(0.04)
3 3 2Page 4 of 16
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the genes are independently distributed with:
1. Scenario 1: Uniform [1.5 - , 1.5 + ] for differen-
tial genes and Uniform [- , ]otherwise;
2. Scenario 2: 2 Beta(0.5, 0.5) -  + 1.5 for differen-
tial genes and 2 Beta(0.5,0.5) -  otherwise;
3. Scenario 3: Gamma(l/4, 1/2) + 1 for differential genes
and Gamma(l/4, 1/2) - 0.5 otherwise.
Under all three scenarios, the differentially expressed
genes for the diseased subjects have mean 1.5 and vari-
ance 1, and non-differential genes have mean 0 and vari-
ance 1. Based on 200 replicates, the mean AUCs are 0.99
(0.01), 0.99 (0.01) and 0.98 (0.04) under scenarios 1–3,
respectively, where the values in the parentheses are the
corresponding standard errors. The mean classification
errors are 0.05 (0.04), 0.04 (0.04) and 0.07 (0.05), respec-
tively.
Colon and estrogen data
Data description
Colon data
In this dataset, expression levels of 40 tumor and 22 nor-
mal colon tissues for 6500 human genes are measured
using the Affymetrix gene chip. A selection of 2000 genes
with the highest minimal intensity across the samples has
been made by [14], and these data are publicly available
at [15]. The colon data have been analyzed in several pre-
vious studies using other statistical approaches, see for
example [1,11,16-18].
Estrogen data
This dataset was first presented by [3,4]. It includes expres-
sion values of 7129 genes of 49 breast tumor samples. The
expression data were obtained using the Affymetrix gene
chip technology and are available at [19]. The response
describes the status of the estrogen receptor (ER). Among
the 49 samples, 25 are positive (ER+) and 24 are negative
(ER-). We threshold the raw data with a floor of 100 and
a ceiling of 16000. Genes with max(expression)/
min(expression) < 10 and/or max(expression) - min(expres-
sion) < 1000 are also excluded [20]. 3332 (46.7%) genes
pass the first step screening. A base 2 logarithmic transfor-
mation is then applied. The estrogen data have also been
studied by [11,16].
Estimation
The ROC estimate is identifiable only up to a scale con-
stant [8]. So prior to the analysis, we need to identify the
"anchor biomarker," i.e, the gene whose estimated coeffi-
cient will be set as a constant for identifiability purposes.
We select the anchor biomarker as follows. Compute the
sample standard errors of the d biomarkers se(1), ..., se(d)
and denote their median as med.se. Compute the adjusted
standard errors as 0.5(se(1) + med.se), ..., 0.5(se(d) + med.se).
Then the biomarkers are ranked based on the t-statistics
computed with the adjusted standard errors. This adjusted
t-statistic is similar to a simple shrinkage method dis-
cussed in [21]. It has been observed in microarray studies
that the standard t-statistic can be very large even if there
is very little difference between the mean expressions (for
the diseased and healthy classes), due to the small vari-
ance estimate caused by small sample size [13]. So com-
pared with the standard t-statistic, the adjusted t-statistic
takes into account variability as well as fold change. The
biomarker with the largest absolute value of the adjusted
t-statistic is chosen as the anchor biomarker. For the
anchor biomarker, if the sample mean of the diseased
class is larger, β(1) = 1.0, otherwise β(1) = -1.0.
Further investigation of the genes that have passed the first
step screening shows that quite a few of those genes have
very little variations across sample. Including such genes





Table 3: Simulation study III. Means of AUC and classification error (with their standard errors in parentheses) for π = 0.05 and 
moderate mean differences. Marginal distributions: Uniform[- , ] and Normal(0, 1). Independent, weakly correlated and 
strongly correlated genes.
Uniform Normal
(nH, nD) Independent Weak Strong Independent Weak Strong
(15, 15) AUC 0.92(0.08) 0.91(0.08) 0.91(0.09) 0.92(0.09) 0.91(0.09) 0.90(0.10)
Error 0.12(0.13) 0.14(0.13) 0.14(0.13) 0.12(0.13) 0.12(0.12) 0.14(0.12)
(20, 10) AUC 0.92(0.08) 0.91(0.10) 0.91(0.08) 0.92(0.08) 0.91(0.09) 0.89(0.10)
Error 0.13(0.12) 0.12(0.13) 0.13(0.13) 0.11(0.13) 0.13(0.13) 0.13(0.12)
(50, 50) AUC 0.99(0.01) 0.98(0.01) 0.98(0.02) 0.99(0.01) 0.98(0.02) 0.98(0.02)
Error 0.04(0.04) 0.05(0.04) 0.06(0.04) 0.04(0.04) 0.05(0.05) 0.07(0.05)
(70, 30) AUC 0.98(0.01) 0.98(0.02) 0.97(0.02) 0.98(0.02) 0.98(0.02) 0.97(0.03)
Error 0.04(0.04) 0.04(0.04) 0.06(0.05) 0.05(0.04) 0.05(0.05) 0.07(0.05)
3 3Page 5 of 16
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data (3332 for the estrogen data) will be associated with
the outcome. So we only use the 500 genes with the larg-
est absolute values of the adjusted t-statistics for classifica-
tion. The genes are then standardized to have zero means
and unit variances. The same anchor marker detection
and pre-processing have been considered in [11] and are
shown to be well-behaved.
Note that there is no computational limitation on how
many genes can be used in the ROC classification. Empir-
ical studies in [13] show that the performance of certain
statistical approaches decreases dramatically as the
number of genes increases. So it is believed that identifi-
cation of the top 500 genes will help to generate more reli-
able estimate.
We use three-fold cross validation for tuning parameter
selection. We show in Table 4 the number of genes with
nonzero coefficients and the CV scores for each fixed
threshold value τ. It can be seen that generally the number
of nonzero coefficients decreases as τ increases. However,
the change of CV score is very small. Our extensive empir-
ical studies show that in general a larger τ will lead to a
more parsimonious model. Parsimonious models are pre-
ferred when the CV scores are comparable. So we choose
τ = 1.0 for both datasets.
In the TGDR, variable selection is achieved by threshold-
ing some estimated coefficients to be exactly zero based
on their derivatives, so the corresponding covariates are
not selected in the final model. The genes in Tables 5 and
6 have nonzero coefficients and other genes have esti-
mated coefficients zero and hence not selected. Since the
gene expressions have been normalized to have unit vari-
ances, the estimated coefficients are directly comparable.
Larger absolute values of coefficients indicate stronger
influences.
More detailed information about these genes can be
found on the NCBI website. For example, for the colon
data, Hsa.949 is from the interleukin 32 gene (IK32). This
gene encodes a member of the cytokine family. Expression
of this protein is increased after the activation of T-cells by
mitogens or the activation of NK cells by IL-2. This protein
induces the production of TNFalpha from macrophage
cells. Hsa.8219 (gene symbol: CDKN1A) encodes a
potent cyclin-dependent kinase inhibitor. The encoded
protein binds to and inhibits the activity of cyclin-CDK2
or -CDK4 complexes, and thus functions as a regulator of
cell cycle progression at Gl. The expression of this gene is
tightly controlled by the tumor suppressor protein p53,
through which this protein mediates the p53-dependent
cell cycle G l phase arrest in response to a variety of stress
stimuli. This protein can interact with proliferating cell
nuclear antigen (PCNA), a DNA polymerase accessory fac-
tor, and plays a regulatory role in S phase DNA replication
and DNA damage repair. Hsa.627 encodes a protein that
is a member of the CXC chemokine family. This chemok-
ine is one of the major mediators of the inflammatory
response and is secreted by several cell types. It functions
as a chemoattractant, and is also a potent angiogenic fac-
tor. This gene is believed to play a role in the pathogenesis
of bronchiolitis, a common respiratory tract disease
caused by viral infection. This gene and the other ten
members of the CXC chemokine gene family form a
chemokine gene cluster in a region mapped to chromo-
some 4q.
For the estrogen data, D43772 (gene symbol: GRB7)
encodes a protein belonging to a small family of adapter
proteins that are known to interact with a number of
receptor tyrosine kinases and signaling molecules. This
gene encodes a growth factor receptor-binding protein
that interacts with epidermal growth factor receptor
(EGFR) and ephrin receptors. The protein plays a role in
the integrin signaling pathway and cell migration by bind-
ing with focal adhesion kinase (FAK). K02054 (gene sym-
Table 4: Colon and estrogen data. Model features for different τ. Variable: number of genes with nonzero coefficients.
Colon Estrogen
τ variable CV variable CV
1.0 18 2.64 20 2.93
0.9 26 2.61 27 2.93
0.8 73 2.63 79 2.93
0.7 278 2.70 139 2.93
0.6 453 2.74 307 2.94
0.5 481 2.76 422 2.94
0.4 492 2.79 490 2.96
0.3 498 2.81 499 2.97
0.2 500 2.76 500 2.97
0.1 500 2.74 500 2.97
0.0 500 2.74 500 2.97Page 6 of 16
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of gastrin-releasing peptides. Its preproprotein, following
cleavage of a signal peptide, is further processed to pro-
duce either the 27 aa gastrin-releasing peptide or the 10 aa
neuromedin C. These smaller peptides regulate numerous
functions of the gastrointestinal and central nervous sys-
tems, including release of gastrointestinal hormones,
smooth muscle cell contraction, and epithelial cell prolif-
eration. These peptides are also likely to play a role in
human cancers of the lung, colon, stomach, pancreas,
breast, and prostate. U03057 (gene symbol: FSCN1) plays
a role in a number of diseases. For example, it impacts the
progression of hormone receptor-negative breast cancer.
It is also expressed in cutaneous CD30+ lymphoprolifera-
tive disorders and is a candidate marker of disease pro-
gression. X03635 (gene symbol: ESR1) is the estrogen
receptor (ESR) that is a ligand-activated transcription fac-
tor composed of several domains important for hormone
binding, DNA binding, and activation of transcription.
Evaluation
We first randomly partition the data into training and test-
ing sets. We then identify the top 500 genes with the larg-
est adjusted t-statistics based on the training sets only. So
the 500 genes used in each individual partition and com-
putation may be different, although there is considerable
overlap.
The occurrence index, which measures the relative stabil-
ity of individual selected genes in the joint model, is
shown in Figures 1 and 2 for the colon and estrogen data,
respectively. We observe that many genes selected with the
proposed approach have relatively high occurrence index
compared to genes not selected, which suggests that the
ROC estimates are relatively stable for these two specific
datasets. On the other hand, we also see that the occur-
rence index, even for the genes selected, can be low in
absolute terms. Most selected genes have occurrence index
less than 0.50. Similar phenomenon has been observed in
[22]. The genes identified in the final model do not neces-
sarily have the largest occurrence index. For example, in
the colon data the gene with the highest occurrence index
was not selected in the model. This is not surprising since
(a) the objective function is the binormal AUC and the
genes were selected to optimize this objective function;
(b) the genes were selected based on all the available data,
whereas the occurrence index was calculated using parti-
tioned data. The occurrence index is one way to evaluate
the relative importance of the genes after they are selected
and it provides a measure of stability of the genes in the
presence of sampling variation, but it does not measure
the prediction power of the genes. Furthermore, the genes
significantly associated with the outcome in different sub-
sets are not necessarily important when the whole dataset
is used. Thus we do not select genes based on the occur-
rence index.
The classification performance of the proposed method
for the two datasets is evaluated using the Monte Carlo
approach described in the Methods section. Both the
number of random partitions for the observed data and
the number of permutations are 1000. For the colon data,
the ROC estimate has mean AUCs 0.94 (0.05) and 0.50
(0.13) for the OPD and PPD, respectively, where the val-
ues in the parentheses are the standard errors. Corre-
sponding mean classification errors are 0.14 (0.06) for
observed data and 0.44 (0.11) for randomly permuted
data, respectively. In the upper-right panel of Figures 1
Table 5: Colon Data: genes with nonzero coeficients.
GeneID β Gene Description
Hsa.949 0.15 M59807, NATURAL KILLER CELLS PROTEIN 4 PRECURSOR.
Hsa.8219 -1.01 R46753, CYCLIN-DEPENDENT KINASE INHIBITOR 1 (Homo sapiens).
Hsa.10047 0.10 T51849, TYROSINE-PROTEIN KINASE RECEPTOR ELK PRECURSOR.
Hsa.8214 0.40 R62549, PUTATIVE SERINE/THREONINE-PROTEIN KINASE B0464.5.
Hsa.8175 -0.31 H49870, MAD PROTEIN (Homo sapiens).
Hsa.2483 -0.10 D14665, Human mRNA for ORF, complete cds.
Hsa.3016 1.33 T47377, S-100P PROTEIN (HUMAN).
Hsa.5392 0.15 T62947, 60S RIBOSOMAL PROTEIN L24 (Arabidopsis thaliana).
Has.341 -0.71 M26683, Human interferon gamma treatment inducible mRNA.
Hsa.1410 1.00 R54097, TRANSLATIONAL INITIATION FACTOR 2 BETA SUBUNIT (HUMAN).
Hsa.2928 0.54 X63629, H.sapiens mRNA for p cadherin.
Hsa.9246 -0.40 T47383, ALKALINE PHOSPHATASE, PLACENTAL TYPE 1 PRECURSOR.
Hsa.1240 -0.30 M31994, Human cytosolic aldehyde dehydrogenase (ALDH1) gene, exon 13.
Hsa.1454 -0.96 M82919, Human gamma amino butyric acid receptor beta-3 subunit mRNA.
Hsa.627 1.00 M26383 Human monocyte-derived neutrophil-activating protein (MONAP) mRNA.
Hsa.2688 0.25 X60489, Human mRNA for elongation factor-1-beta.
Hsa.6814 0.51 H08393, COLLAGEN ALPHA 2(XI) CHAIN (Homo sapiens).
Hsa.1491 0.94 M35531, Human GDP-L-fucose:beta-D-galactoside 2-alpha-l-fucosyltransferase mRNA.Page 7 of 16
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OPD and PPD of the AUC. We can see that the two distri-
butions are well separated. A simple Wilcoxon test of the
difference of these two distributions gives p-value <
0.0001. For the same dataset and using the top ranked 200
genes based on the marginal Wilcoxon rank test, Table 1
in [16] shows that the mean classification errors are 0.16
(LogitBoost, 100 iterations), 0.18 (AdaBoost), 0.18 (1-
nearest-neighbor) and 0.15 (classification tree). In [17],
2000 genes are used and the SVM based methods have
mean AUCs 0.85 and mean classification errors 0.18,
whereas the principal component analysis based
approaches have even smaller AUCs and larger classifica-
tion errors. Using the same set of 500 genes, the logistic-
LASSO method in [11] has mean AUCs 0.88 and mean
classification errors 0.08; the SMRC method in [11] has
mean AUCs 0.91 and mean classification errors 0.14. So
for the colon data, the proposed binormal ROC method
performs better than other approaches in terms of AUC
and classification error, although the improvement is not
dramatic since most other approaches behave reasonably
well. We also note that since different sets of genes are
used in [16,17], the above results can only provide a
rough comparison.
For the estrogen data, the proposed ROC estimate has
mean AUCs 0.95 (0.05) and 0.50 (0.14) for the OPD and
PPD, respectively, with corresponding mean classification
errors 0.08 (0.06) and 0.48 (0.12). For the same dataset,
Dettling and Buhlmann (2003, Table 1) use 200 genes
selected based on the marginal Wilcoxon tests and yield
classification errors 0.04, 0.06 and 0.08 with different
LogitBoost methods, classification error 0.04 for Ada-
Boost, 0.14 for 1-nearest-neighbor approach and 0.04 by
using the classification tree. Using the same set of genes,
the logistic-LASSO [11] has mean AUCs 0.92 and mean
classification errors 0.12; whereas the SMRC [11] has
mean AUCs 0.96 and mean classification errors 0.06.
Note that in our study, joint models are considered, i.e, we
consider the joint effects instead of marginal effects of
genes. Identification of differentially expressed genes
associated with clinical outcomes based on marginal sig-
nificance has been well investigated and accepted. So as a
simple evaluation, we show the marginal binormal AUC
and t-statistic for each individual gene in Figures 1 and 2.
Similar evaluation has been considered in [23] as a gene
ranking method. We can see from Figures 1 and 2 that sev-
eral genes we identify do have large marginal binormal
AUCs and t-statistics; both up- and down- regulated genes
are identified in the final models. However, we also iden-
tify some genes with small binormal AUCs or small t-sta-
tistics. It is believed that these genes are important in the
joint models, but not in the marginal models. Variable
selection using TGDR looks at all the variables and con-
siders the relative importance of each variable in terms of
its contribution to change in the objective function, but is
not based on marginal significance. So the results do not
necessarily correspond to those based on marginal signif-
icance.
When binormal ROC method is used, it is of interest to
examine whether the ROC curve is concave. Pepe [8]
pointed out the binormal ROC is not concave when the
variances of the two groups are not equal. However, she
also pointed that "Swets (1986) and Hanley (1988, 1996)
conclude that the binomal ROC curve provides a good
approximation to a wide range of ROC curves that occur
in practice [24-26]. This may be because the undesirable
behavior of the approximating binormal ROC usually
occurs over a very small part of the ROC curve." As a sim-
ple check, we show in Figure 3 the plots of binormal ROC
for a randomly selected training set and a testing set. We
can clearly see the concavity of the binormal ROC. Exam-
ination of other training and testing sets shows similar
results.
We note that although the genes identified using the two
datasets exhibit strong predictive power for disease sta-
tuses as demonstrated above, the analysis here does not
provide information on whether they are just genomic
markers correlated with the disease statuses or are actually
in the pathways leading to the diseases. Indeed, as is typi-
cal with microarray results, further investigation based on
independent assays and/or independent samples is desir-
able.
Conclusion
The ROC method has been successfully used for disease
classification using low- dimensional biomarkers. The
empirical AUC method has been successfully imple-
mented in [11]. In this article, we propose using the binor-
mal AUC, which is a useful alternative to the empirical
AUC, as the objective function for disease classification
using high dimensional genomic data. The scaled TGDR is
employed for regularization and biomarker selection.
Extensive simulation studies and applications to two can-
cer data show that the proposed approach can generate
satisfactory classification results with a small number of
identified biomarkers with biologically sound implica-
tions. Although theoretically the binormal AUC is con-
structed under the normal distribution assumption, the
proposed approach still behaves satisfactorily when this
assumption is seriously violated. Beyond the merits car-
ried by the ROC method, the proposed approach has the
advantage of little computational cost. Using the scaled
gradient significantly reduces the computational com-
plexity. It takes only a few seconds to analyze dataset with
1000 genes and 100 subjects using R [27] code, whereasPage 8 of 16
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longer.
In our data analyses, we selected 500 genes with the larg-
est adjusted t-statistics. The proposed approach has no
limitation on the number of genes that can be used in the
final model. We note that use of 500 genes is somewhat
subjective. Same analyses with 200 genes and all the genes
have also been carried out (results not shown), and there
are considerable overlaps among genes identified. We pre-
fer using 500 genes because this set of genes should
include most (if not all) important genes without includ-
ing too much noise. We used the same datasets as in [11].
Although both methods are ROC based and the same sets
of genes are used, the identified biomarkers are different.
Considering that both the empirical AUC and the binor-
mal AUC methods are extensively used, such difference
warrants further investigation and confirmation by inde-
pendent studies.
In our study, the adjusted t-statistic is used instead of the
standard t-statistic. The reason we used the adjusted t-sta-
tistic is that the unadjusted t-statistics can be large for
genes with small mean differences in expression levels, if
the standard error is very small. Because of a large number
of genes on each array, there will usually be genes with
very small standard errors, and some of these genes will
have small means as well. This phenomenon has been dis-
cussed by [28] in motivating their adjusted t-statistic for
significance analysis of microarrays (SAM). Similar vari-
ance adjust has also been considered in [29]. However, a
recent study [30] points out that such variance adjust may
not be necessary. Since current study is not conclusive, we
use the adjusted t-statistic and leave the choice of t-statis-
tic versus adjusted t-statistic to a future study.
In this paper, we proposed Monte Carlo based methods
for evaluation of prediction and stability of individual
genes. The proposed methods are closely related to cross
validation and permutation methods. The problem of
evaluation is extremely important for high dimensional
classification, but it has not been extensively studied.
Although the proposed methods have sound, intuitive
implications, further studies of their theoretical properties
would be of interest.
We focus on the linear combination of genes that maxi-
mizes the binormal-AUG. In [31], linear combinations of
genes favoring certain specificity or other criterion are
investigated. If maximization of specificity is of interest,
we can then combine Liu's methods with certain variable
selection techniques, for example LASSO or the proposed
TGDR. We leave this to a future study. We only discussed
two-sample classification in this article. When extension
of the binormal AUC to multi-class study exists, the pro-
posed estimation and regularization method can be used.




Consider a study with n subjects, where the outcome Y is
a binary random variable with the values 0 and 1 denoting
the absence and presence of disease, respectively. For the
Table 6: Estrogen data: genes with nonzero coeficients.
GeneID β Gene Description
AB002365_at 0.06 AB002365, Human mRNA for KIAA0367 gene, partial cds.
D43772_at -0.10 D43772, Human squamous cell carcinama of esophagus mRNA for GRB-7 SH2 domain protein.
D87468_at -0.61 D87468, Human mRNA for KIAA0278 gene, partial cds.
HG2755-HT2862_at 0.10 T-Plastin.
J02871_s_at 0.35 J02871, Human lung cytochrome P450 (IV subfamily) BI protein, complete cds.
K02054_at 0.55 K02054, Human gastrin-releasing peptide mRNA, complete cds.
K03460_at -0.06 K03460, Human alpha-tubulin isotype H2-alpha gene, last exon.
M11718 _at 0.05 M11718, Human alpha-2 type V collagen gene, 3' end.
M24069_at 0.25 M24069, Human DNA-binding protein A (dbpA) gene, 3' end.
M32053_at 0.45 M32053, Human H19 RNA gene, complete cds (spliced in silico).
M81758_at -0.10 M81758, Homo sapiens skeletal muscle voltage-dependent sodium channel alpha subunit (SkM1) mRNA.
M83186_at 0.05 M83186, Human cytochrome c oxidase subunit VIIa (COX7A) muscle isoform mRNA, complete cds.
U01062_at -0.20 U01062, Human type 3 inositol 1,4,5-trisphosphate receptor (ITPR3) mRNA, complete cds.
U03057_at 0.15 U03057, Human actin bundling protein (HSN) mRNA, complete cds.
U28386_at 0.05 U28386, Human nuclear localization sequence receptor hSRP1alpha mRNA, complete cds.
U60115_at 0.05 U60115, Human skeletal muscle LIM-protein SLIM1 mRNA, complete cds.
U82169_at -0.40 U82169, Human frizzled homolog (FZD3) mRNA, complete cds.
X03635_at 1.00 X03635, Human mRNA for oestrogen receptor.
X56667_at -0.20 X56667, Human mRNA for calretinin.
X86693_at 0.10 X86693, H.sapiens mRNA for hevin like protein.Page 9 of 16
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BMC Bioinformatics 2006, 7:253 http://www.biomedcentral.com/1471-2105/7/253ithsubject, expression values of d genes, i = (Xi,1, ..., Xi,d),
are measured. When using the ROC classification, we pre-
dict the phenotype Y based on the "linear risk scores"
β' , where β = (β(1), ..., β(d)) is a d-dimensional vector of
regression parameters and β' denotes its transpose. For
example, we classify Y = 1 if β'  > c, for a cutoff c chosen
based on the estimated ROC, otherwise Y = 0. When a
semiparametric single index model P(Y = 1| ) = G(β' )
is assumed, the ROC classification is optimal [10]. Here G
is an unspecified increasing link function. Note that when
the single index model assumption is violated, the ROC
method, although no longer optimal, still provides mean-
ingful classification results [8,10].
ROC method
To evaluate the performance of a classifier based on the
linear risk scores β'  with different choices of β, we
employ the widely used measurements of classification
accuracy in medicine, namely the true and false positive
rates (TPR and FPR). Also known as sensitivity and 1-spe-
cificity, respectively, TPR and FPR are defined as
TPR(c) = P(β'  ≥ c|Y = 1) and FPR(c) = P(β'  ≥ c|Y = 0),
for any cutoff c. The TPR and FPR can be summarized by
the ROC curve, which is a two-dimensional plot of
{(FPR(c), TPR(c)) : -∞ <c < ∞}. The ROC curve demon-
strates the balance between the true positive and false pos-
itive rates. Classification rules that have (FPR(c),TPR(c))
close to (0,1) indicate satisfactory discriminators, while
those with (FPR(c), TPR(c) near the 45° line cannot dis-
criminate between the diseased and non-diseased classes.
For the n subjects, denote  and  as the index sets for the
diseased and non-diseased subjects with sizes nD and nH,
respectively. Let D denote the biomarkers of a diseased
subject and H the biomarkers of a non-diseased subject.
The overall performance of a classifier can be measured by
the AUC, with larger AUC indicating better performance.
For any linear risk score β' , the empirical AUC is
where I(·) is the indicator function. Pepe [10] proposes to
maximize (1) to obtain an optimal linear risk score. [11]
extends Pepe's work to high dimensional settings by con-
sidering a Sigmoid approximation of the empirical AUC.
Alternatively, we consider the binormal AUC. Assume that
D and H, after a common monotone transformation,
have normal distributions D ~ N(μD, ΣD) and H ~
N(μH, ΣH), respectively. Under this so-called binormal
model, the AUC can be written as [8]
where Φ is the normal distribution function. For a sample
with n subjects, the binormal AUC can be estimated by
where  and  denote the sample mean and the sample
variance-covariance matrix, respectively. We propose
using (3) as the objective function for two-sample classifi-
cation from microarray data. Define the ROC estimator of
β as:
We note that this estimator is only identifiable up to a
scale constant. Without loss of generality, we assume |β(1)|
= 1.0, where β(1) denotes the first component of β, i.e, the
first biomarker is the "anchor biomarker." We suggest a
simple way of determining the anchor biomarker in the
Results section.
The binormal AUC (2) is obtained under the normal dis-
tribution assumption. As pointed out by Pepe [8], "the
binormal ROC curve plays a central role in ROC analysis.
In much the same way that the normal distribution is a
classic model for distribution functions, the binormal
ROC curve is a classic model for ROC curves." When the
normal distribution assumption does not hold, the objec-
tive function (3) still generates a meaningful estimate, i.e,
using the linear combination of genes that maximizes
classification power as measured by the AUC. For refer-
ence, see [8]. Simulation studies under model mis-specifi-
cation are provided in the Results section.
Regularized estimation
Maximization of the binormal AUC with low dimen-
sional covariates has been investigated in [31]. With large
sample size and a small number of covariates, the maxi-
mizer in [31] is unique and well-defined and variable
selection is not of interest. However with the microarray
data, there exist multiple maximizers of the binormal
AUC; moreover, variable selection is needed along with
estimation. So regularized estimation, through which
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BMC Bioinformatics 2006, 7:253 http://www.biomedcentral.com/1471-2105/7/253addition, the following regularization method provides a
way of variable selection.
For simplicity of notation and without loss of generality,
we assume that the first biomarker is the anchor and β(1)
= 0.1, and we still use β to denote the remaining coeffi-
cients (β(2), ..., β(d))'. The TGDR approach was originally
proposed for the linear regression [7]. This method first
establishes a parameter path in the high dimensional
coefficient space using the gradient descent method, and
then identifies the best model along the parameter path
with certain cross validation techniques. Here we adapted
this method to the binormal AUC. Let β(v) denote the
parameter path indexed by v ∈ [0, ∞). Let Δv be the infin-
itesimal positive increment as in ordinary gradient
descent methods [7]. In implementation of this algo-
rithm, we choose Δv = 1 × 10-4. For any threshold 0 ≤ τ ≤
1, the TGDR algorithm consists of the following iterative
steps:
1. Initialize β(0) = 0 and v = 0.
2. Compute the relative gradient function g(v), where g(v)
= -∂ (β)/∂β × s(v) and s(v) is a positive scale
function depending on the data and v Denote the jth com-
ponent of g(v) as gj(v). If maxj{|gj(v)|} = 0, stop the itera-
tions. Otherwise, g(v) = g(v)/maxj{|gj(v)|}.
3. Compute the vector f(v) of length d, where the jth com-
ponent of f(v) is fj(v) = I{|gj(v)| ≥ τ·maxl|gl(v)|}.
4. Update β(v + Δv) = β(v) + Δv × g(v) × f(v) and replace v
by v + Δv, where the product of f and g is component-wise.
5. Steps 2–4 are repeated k times. The number of iterations
k is determined by cross validation as described below.
When maxl{|gl(v)|} is less than a pre-specified criterion,
the iteration can be stopped. We recommend tracking the
AUCnnormal
Colon dataFigure 1
Colon data. X axis: natural order of genes. Left-upper panel: occurrence index, red "+": genes identified with the TGDR. 
Right-upper panel: kernel density estimation of the OPD (solid line) and PPD (dashed line) of AUG. Left-lower panel: Binormal 
AUC of every gene. Lower-right panel: t-statistics of every gene.
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BMC Bioinformatics 2006, 7:253 http://www.biomedcentral.com/1471-2105/7/253magnitude of maxl{|gl(v)|} and the plot of the cross vali-
dation function as a function of k to determine the
number of iterations in step 5.
The proposed TGDR has been adapted and modified from
[7], in the sense that the scaled, relative gradient is used
instead of the gradient function in step 2. This modifica-
tion is equivalent to using the original gradient, but differ-
ent Δv, at each iteration. So the modified TGDR can still
lead to complete parameter paths, as long as Δv is small
enough. We compute the relative gradient g(v) as follows.
First note:
where ϕ is the normal density function. Set
.
Note that s(v) is positive as long as β has nonzero compo-
nents. The relative gradient
has less computational cost compared to the original gra-
dient. Although the modification is not dramatic, it can
reduce the computational time from minutes to seconds
with high dimensional data.
Detailed discussions of the TGDR algorithm can be found
in [7] where a graphic presentation is also available (Fig-
ures 1 and 3 therein). The tuning parameters τ and k
jointly determine the property of . Stable estimates are
expected with non-zero τ, since τ guarantees that only cov-
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Estrogen dataFigur  2
Estrogen data. X axis: natural order of genes. Left-lower panel: occurrence index, red "+": genes identified with the TGDR. 
Right-lower panel: kernel density estimation of the OPD (solid line) and PPD (dashed line) of AUC. Left-lower panel: Binormal 
AUC of every gene. Lower-right panel: t-statistics of every gene.
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BMC Bioinformatics 2006, 7:253 http://www.biomedcentral.com/1471-2105/7/253ariates with large gradients are included in the model.
Loosely speaking k measures convergence and more
importantly the complexity of the model: for a fixed τ,
smaller k leads to more parsimonious models. Specifically
when τ ≈ 0,  is dense for all values of k. When τ ≈ 1, 
is sparse for small k and remains so for a relatively large
number of iterations, but will become dense eventually.
At the extreme when τ = 1, the TGDR usually increases in
the direction of a single covariate in each iteration. This
mimics the incremental forward stage-wise strategy
described in [32]. When τ is in the middle range, the char-
acteristics of  are between those for τ = 0 and τ = 1. The
threshold parameter τ is constrained in the interval [0, 1].
Unfortunately, as for other gradient search or boosting
approaches, there is no clear bound for the parameter k.
Usually we need to carry out the iterations until a well-
defined maximizer of the CV score to carry out the itera-
tions until a well-defined maximizer of the CV score is
found.
In a linear regression model, [7] shows that the TGDR can
provide a path connecting the solutions roughly corre-
sponding to the PLS/RR (ridge regression) and the solu-
tions roughly corresponding to the LASSO by varying the
thresholds. Moderate to large threshold values create
paths that involve more diverse absolute coefficient values
than the PLS/RR but less than the LASSO. Our numerical
studies suggest that the conclusions drawn from the linear
regression are applicable here.
As for other regularized variable selection approaches, we
identify the best predictive model using cross validation.
Usually in the final model, only a fraction of the estimated
coefficients are nonzero, and those nonzero coefficients
correspond to covariates importantly associated with the
outcome. In certain variable selection approaches like the
step-down, variable selection is achieved by excluding var-
iables with marginal measurements like the p-values
greater than certain cutoff. In the TGDR approach, varia-
ble selection is obtained by setting the coefficients corre-
sponding to noisy variables zero. We can see from the
algorithm description that there is no requirement on d
for a given n. So when using the TGDR, we usually do not
carry out a preliminary gene selection.
Tuning parameter selection
We use V-fold cross validation [33] to select the tuning
parameter k for a given τ. For a pre-defined integer V, par-
tition the dataset randomly into V non-overlapped sub-
sets of equal sizes. Choose k to maximize the cross-
validated objective function
where (-v) is the proposed estimate of β based on the
data without the vth subset for a fixed k and  is
the function  defined in (3) evaluated with the
vth subset only. Since the CV score defined in (5) involves
computation of the binormal AUC, which measures the
difference between two phenotype classes, the usual
leave-one-out cross validation is not applicable here.
Since the performance of the TGDR estimates for different
threshold values is of interest, we employ cross validation
with respect to k only. In addition, cross validation over
both k and τ will lead to models with slightly better pre-
diction performance (than model achieved by cross vali-
dation over k only) but too many genes, hence unstable
βˆ βˆ
βˆ
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BMC Bioinformatics 2006, 7:253 http://www.biomedcentral.com/1471-2105/7/253models. We have discussed the effect of different τ in the
application. Related discussions can also be found in [34].
Beyond selecting the model (corresponding to the cross
validated tuning parameters) with the best predictive per-
formance, the V-fold cross validation also provides partial
protection against overfitting [1].
The purpose of cross validation is to select the tuning
parameters for estimating the parameter β. In practice, to
evaluate how the model fit the data, the data set is usually
divided into a training set and a test set (See the usage of
this technique below in prediction performance evalua-
tion). The parameter β is first estimated using the training
set and the estimate is then applied to the test set for eval-
uation of the model. Thus the cross validation process is
only used in the first step.
Occurrence index
In "classic" classification studies, the standard approach
for assessing the significance of a covariate is to use the p-
value of its z-score, which is computed as the ratio of the
estimated coefficient over its estimated standard error.
However, when the sample size is smaller than or compa-
rable to the number of covariates, this standard approach
may not be appropriate, since its validity typically relies
on the assumption n >> d.
In classification using microarray data, it is important to
assess the relative importance and stability of genes, espe-
cially the genes identified to be correlated with the out-
come. Motivated by the methods of [35,36], we propose
the following measure for assessing the relative impor-
tance and stability.
1. We first generate perturbation of the data by randomly
sampling n1 subjects. We propose n1 ~ 2/3n.
2. The TGDR approach (including cross validation and
evaluation) is then applied to the sampled subset. Repeat
this procedure B (for example 1000) times.
3. For the jth covariate, compute the number of times cj it
is included in the final model (the estimated coefficient is
not zero) based on the B perturbed estimates. Then the
proportion oj = cj/B gives a measure of the relative impor-
tance and stability of the jthcovariate.
We call oj the occurrence index of the jth covariate. It lies
between 0 and 1. We generate a large number of realiza-
tions of data with the same distribution as the observed
data by partition. So loosely speaking, the occurrence
index measures the stability of individual genes identified
using the proposed approach. A higher occurrence index
indicates a more stable and relatively more important
gene.
The occurrence index shares the same spirit as the gene fre-
quency in [22]. They both measure the stability of discov-
ered genes using random sampling method. The essential
difference is that in this paper, we consider joint models,
i.e., the linear combinations of genes; whereas in [22] the
marginal models are considered, i.e, the models with indi-
vidual genes.
Prediction performance evaluation
The following prediction performance evaluation is pro-
posed in [11]. We refer to that paper for details. For com-
pleteness of this article, we briefly describe it below. The
essence of the proposed approach is to evaluate prediction
significance using randomly permuted and partitioned
data.
Observed predictive distribution of AUC
1. We first partition the data randomly into a training set
of size n1 and a testing set of size n2 with n1 + n2 = n. Dudoit
[20] suggests n1 ~ 2/3n.
2. We use the training set to compute the ROC estimator.
The binormal AUC for the testing set is then computed
using this training set estimate.
3. To take into account the fact that we may get a large
value of the AUC by chance with a "lucky" partition, we
repeat this process many (for example 1000) times. Each
time a new partition is made and the testing set AUC is
computed.
With this procedure, we obtain a Monte Carlo estimation
of the distribution of the prediction AUC by partitioning
the observed data. We call it the observed predictive distribu-
tion (OPD) of AUC, which provides an honest measure of
the classification performance of the proposed methodol-
ogy. The OPD can be used to compare the relative per-
formance of two approaches/estimates.
Permutation predictive distribution of AUC
We first randomly permute the binary outcome Y, but
keep the indices of the covariates fixed. We then couple
the permuted outcome with the covariates. We permute
the data 1000 times. Each time, we partition the permuted
data into a training set of size n1 and a testing set of size
n2, and compute the testing set AUC in the same manner
as described above. This yields the Monte Carlo distribu-
tion of the AUC with permuted data, i.e., the permutation
predictive distribution (PPD) of AUC.
Well separated OPD and PPD distributions indicate that
the model estimated with the proposed approach is effec-
tive in terms of prediction, whereas substantially over-
lapped distributions suggest that either the proposedPage 14 of 16
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good discriminant power.
We note that there are at least two possible approaches for
evaluating prediction performance, one is based on cross-
validation which randomly partitions the data into a
training set and a test set, the other uses the bootstrap.
Both approaches are equally valid. For detailed discus-
sions, see Chapter 7 (in particular, Sections 7.10 and 7.11)
of [32]. The approach we take is based on cross-valida-
tion, but beyond this, we used many random partitions to
obtain the observed prediction distribution (OPD), and
then compare it to the permutation prediction distribu-
tion (PPD), to evaluate the model significance in terms of
prediction. According to [32], evaluation of prediction
performance based on random partition or bootstrap are
equally justified. In our case, we believe that random par-
tition is more intuitive and computationally simpler. In
the bootstrap approach, the standard bootstrap actually
gives biased estimation, since it samples the data with
replacement. Instead, one needs to use a "0.632 boot-
strap" to avoid the bias and other subtle adjustments are
needed, again, see [32].
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